Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metagenomi TherapeuticsMGX -0.81%10 EV-to-EBIT is 0.37 as of Aug. 18, 2026, which is 62% below its 10-year median of 0.97. GuruFocus rates MGX with a GF Score™ of 10/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 370 Biotechnology companies, Metagenomi Therapeutics ranks better than 87.03% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Metagenomi Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $-37.99 Mil.
Metagenomi Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics EV-to-EBIT Related Terms
Metagenomi Therapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Metagenomi Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's EV-to-EBIT falls into.
Metagenomi Therapeutics's current Enterprise Value is $-36.86 Mil.
Metagenomi Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a EV-to-EBIT of 0.37 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Metagenomi Therapeutics and its competitors. This is 62% below median its historical median of 0.97. According to the industry distribution chart, Metagenomi Therapeutics ranks #48 out of 370 companies in the Biotechnology industry, placing it in the top 13%.
Is Metagenomi Therapeutics' EV-to-EBIT too high?
Metagenomi Therapeutics' current EV-to-EBIT of 0.37 is 62% below median its 10-year median of 0.97. The Biotechnology industry median EV-to-EBIT is 16.12. Metagenomi Therapeutics' value of 0.37 is 97.7% below this industry median. Based on the distribution chart, Metagenomi Therapeutics ranks #48 out of 370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' EV-to-EBIT compare to BYSI and EXOZ?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #48 out of 370 companies for EV-to-EBIT. This places Metagenomi Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.12. Metagenomi Therapeutics' value of 0.37 is 97.7% below this benchmark. While the company's 10-year median is 0.97 vs. the industry median of 16.12, Metagenomi Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metagenomi Therapeutics's current EV-to-EBIT of 0.37 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Metagenomi Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current EV-to-EBIT is 0.37, which is 62% below median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $1.23 — trading 78.3% above its estimated fair value. The current EV-to-EBIT is 0.37, which is 62% below median its 10-year median of 0.97 and 97.7% below the Biotechnology industry median of 16.12. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current EV-to-EBIT is 0.37 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metagenomi Therapeutics (MGX) Overvalued in 2026?
Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued.
The current stock price of $1.23 is trading 78.3% above its estimated GF Value™ of $0.69.
GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.
Key valuation signals for MGX:
EV-to-EBIT: 0.37 (62% below median its 10-year median of 0.97)
GF Value™: $0.69 vs. price of $1.23 (78.3% above fair value)
Industry Position: 97.7% below the Biotechnology median (#48 of 370)
No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
